



(51) **International Patent Classification:**
C07D 487/06 (2006.01) **A61P 35/00** (2006.01)
A61K 31/55 (2006.01)

(21) **International Application Number:**
PCT/IB2011/050571

(22) **International Filing Date:**
10 February 2011 (10.02.2011)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
61/304,277 12 February 2010 (12.02.2010) US

(71) **Applicant (for all designated States except US):** **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants (for US only):** **BASFORD, Patricia, Ann** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **CAMPETA, Anthony, Michael** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **GILLMORE, Adam** [GB/GB]; Pfizer Global Research & Development, Ramsgate road, Sandwich Kent CT13 9NJ (GB). **JONES, Matthew, Cameron** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **KOUGOULOS, Eleftherios** [GR/US]; 4407 Hopson Road Apartment 2308, Morrisville, North Carolina 27560 (US). **LUTHRA, Suman** [IN/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **WALTON, Robert** [GB/GB]; Pfizer Global Research & Development, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(74) **Agent:** **KLEIMAN, Gabriel, L.;** Pfizer Inc. 235 East 42nd Street, New York, New York 10017 (US).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) **Title:** SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO)METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE



(I)

(57) **Abstract:** The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino(5,4,3-cd)indol-6-one;(I), and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.